RxDoctor Payments Data

Ali Tabrizchi

Interventional Cardiology · Bel Air, MDNPI 1710047709

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $59,055 of the $65,826 with a category attached, or 89.7%. Johnson & Johnson accounts for 67.4% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $54,804 and has fallen 99.7% since, to $152 in 2023.

$65,826in general payments, 2019–2025

Across 372 payments — averaging $176.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$44K
  • Amarin Pharma, Inc.$9K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5K
  • Chiesi USA, Inc.$3K
  • Novartis$659
  • Pfizer$630
  • plus $3K from 24 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$59,05590%
  • Travel & lodging$2620%
  • Food & beverage$6,1109%
  • Education$990%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,826 in reported general payments places this provider in the 85th percentile of 71 interventional cardiology providers in Maryland.

See all interventional cardiology providers in Maryland

Other interventional cardiology in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →